FLVCR2 and cancer: Previous studies reported that the expression levels of different CCT subunits were upregulated in various cancers, such as CCT2 in prostate, breast, and lung cancers (Guest et al., 2015; Bassiouni et al., 2016; Carr et al., 2017), CCT3 in hepatocellular carcinoma (HCC) (Qian et al., 2016), and CCT8 in HCC and glioblastoma (Huang et al., 2014; Qiu et al., 2015).